China vs Lithuania: Hepatitis B surface antigen (HBsAg) prevalence
China
0.1%
in 2024
Lithuania
0.1%
in 2024
China rank
101st
Lithuania rank
101st
Hepatitis B surface antigen (HBsAg) prevalence over time
- China
- Lithuania
How they compare
China currently reports 0.1% against 0.1% in Lithuania, a difference of 0.0%.
The two have swapped places 1 time across 10 shared years of data; in 2015 it was China ahead.
China ranks 101st and Lithuania ranks 101st of 194 countries.
China has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | China | Lithuania | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.2% | 0.1% | 0.1% | China |
| 2020s | 0.1% | 0.1% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher hepatitis b surface antigen (hbsag) prevalence, China or Lithuania?
- China, at 0.1% against 0.1% in Lithuania as of 2024.
- What is the difference in hepatitis b surface antigen (hbsag) prevalence between China and Lithuania?
- 0.0%, with China ahead.
- How many years of comparable data are there for China and Lithuania?
- 10 years are reported by both, from 2015 to 2024.
- How do China and Lithuania rank globally for hepatitis b surface antigen (hbsag) prevalence?
- China ranks 101st and Lithuania ranks 101st of 194 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Hepatitis B surface antigen (HBsAg) prevalence (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.